A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients (ALECSAT-GBM)
This study has been completed.
Sponsor:
CytoVac A/S
Information provided by (Responsible Party):
CytoVac A/S
ClinicalTrials.gov Identifier:
NCT01588769
First received: April 27, 2012
Last updated: April 4, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | April 2013 |
| Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |